KYTX vs LEGN vs CABA vs FATE vs CRSP

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate Kyverna Therapeutics, Inc. (KYTX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -4.

2%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus KYTX's -68. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.

76β versus Kyverna Therapeutics, Inc. 's 2. 99β — meaning KYTX is approximately 295% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Kyverna Therapeutics, Inc. (KYTX) carries a lower debt/equity ratio of 3% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Cabaletta Bio, Inc. grew EPS 29. 9% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kyverna Therapeutics, Inc.

(KYTX) is the more profitable company, earning 0. 0% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYTX leads at 0. 0% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — LEGN leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1552.

7% to $39. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Legend Biotech Corporation (LEGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

76)). Kyverna Therapeutics, Inc. (KYTX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEGN: -24. 0%, KYTX: -68. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KYTX is a small-cap quality compounder stock; LEGN is a small-cap high-growth stock; CABA is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.